AU2013251649B2 - Generating pluripotent cells de novo - Google Patents

Generating pluripotent cells de novo Download PDF

Info

Publication number
AU2013251649B2
AU2013251649B2 AU2013251649A AU2013251649A AU2013251649B2 AU 2013251649 B2 AU2013251649 B2 AU 2013251649B2 AU 2013251649 A AU2013251649 A AU 2013251649A AU 2013251649 A AU2013251649 A AU 2013251649A AU 2013251649 B2 AU2013251649 B2 AU 2013251649B2
Authority
AU
Australia
Prior art keywords
cells
cell
pluripotent
stap
stress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013251649A
Other languages
English (en)
Other versions
AU2013251649A1 (en
Inventor
Koji Kojima
Haruko OBOKATA
Yoshiki Sasai
Charles A. Vacanti
Martin P. Vacanti
Teruhiko Wakayama
Masayuki Yamato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vcell Therapeutics Inc
Original Assignee
Vcell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vcell Therapeutics Inc filed Critical Vcell Therapeutics Inc
Publication of AU2013251649A1 publication Critical patent/AU2013251649A1/en
Assigned to THE BRIGHAM AND WOMEN'S HOSPITAL, INC. reassignment THE BRIGHAM AND WOMEN'S HOSPITAL, INC. Request for Assignment Assignors: RIKEN, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., TOKOYO WOMEN'S MEDICAL UNIVERSITY
Assigned to VCELL THERAPEUTICS, INC. reassignment VCELL THERAPEUTICS, INC. Request for Assignment Assignors: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Application granted granted Critical
Publication of AU2013251649B2 publication Critical patent/AU2013251649B2/en
Priority to AU2019203943A priority Critical patent/AU2019203943B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2013251649A 2012-04-24 2013-04-24 Generating pluripotent cells de novo Active AU2013251649B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019203943A AU2019203943B2 (en) 2012-04-24 2019-06-05 Generating pluripotent cells de novo

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637631P 2012-04-24 2012-04-24
US61/637,631 2012-04-24
US201361779533P 2013-03-13 2013-03-13
US61/779,533 2013-03-13
PCT/US2013/037996 WO2013163296A1 (en) 2012-04-24 2013-04-24 Generating pluripotent cells de novo

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019203943A Division AU2019203943B2 (en) 2012-04-24 2019-06-05 Generating pluripotent cells de novo

Publications (2)

Publication Number Publication Date
AU2013251649A1 AU2013251649A1 (en) 2014-11-06
AU2013251649B2 true AU2013251649B2 (en) 2019-04-04

Family

ID=49483852

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013251649A Active AU2013251649B2 (en) 2012-04-24 2013-04-24 Generating pluripotent cells de novo
AU2019203943A Active AU2019203943B2 (en) 2012-04-24 2019-06-05 Generating pluripotent cells de novo

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019203943A Active AU2019203943B2 (en) 2012-04-24 2019-06-05 Generating pluripotent cells de novo

Country Status (11)

Country Link
US (1) US11963977B2 (enExample)
EP (2) EP2844738A4 (enExample)
JP (5) JP2015516812A (enExample)
KR (2) KR20150045935A (enExample)
CN (2) CN112048466A (enExample)
AU (2) AU2013251649B2 (enExample)
CA (1) CA2885576A1 (enExample)
ES (1) ES2972525T3 (enExample)
RU (1) RU2696071C2 (enExample)
SG (2) SG11201407768QA (enExample)
WO (1) WO2013163296A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2691027C2 (ru) 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
EP2914728B1 (en) 2012-11-01 2020-07-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
WO2014117021A2 (en) 2013-01-25 2014-07-31 Xcell Biosciences, Inc. Methods, compositions, kits, and systems for selective enrichment of target cells
US20160002599A1 (en) 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
KR102527507B1 (ko) 2013-03-15 2023-04-28 아스텔라스 인스티튜트 포 리제너러티브 메디슨 만능 줄기 세포로부터 제조된 광수용기 및 광수용기 전구체
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
WO2014201254A1 (en) 2013-06-12 2014-12-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
CN105940110A (zh) 2014-01-31 2016-09-14 菲克特生物科学股份有限公司 用于核酸产生和递送的方法和产品
ES3006707T3 (en) * 2014-03-19 2025-03-18 Vcell Therapeutics Inc Methods relating to pluripotent cells
WO2016089178A1 (ko) * 2014-12-04 2016-06-09 가톨릭관동대학교산학협력단 에너지를 이용한 다능성 세포 유도 장치 및 방법
US11773387B2 (en) * 2014-12-04 2023-10-03 Stemon Inc. Device and method for inducing pluripotent cells using energy
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10668109B2 (en) * 2015-06-18 2020-06-02 Yeda Research And Development Co. Ltd. Conditioning protocols and use of same for tissue regeneration
KR101855967B1 (ko) * 2016-03-11 2018-05-10 가톨릭관동대학교산학협력단 물리적 자극에 의한 환경유입을 이용한 세포 리프로그래밍 방법
WO2017155166A1 (ko) * 2016-03-11 2017-09-14 가톨릭관동대학교기술지주 주식회사 물리적 자극에 의한 환경유입을 이용한 세포 리프로그래밍 방법
WO2017155167A1 (ko) * 2016-03-11 2017-09-14 가톨릭관동대학교산학협력단 세포 리프로그래밍 장치
KR102050852B1 (ko) * 2016-03-11 2019-12-03 주식회사 스템온 세포 리프로그래밍 장치
US10426796B2 (en) 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
EP3555262A4 (en) * 2016-11-07 2020-05-13 K2 Research Holdings, LLC PRODUCTION AND THERAPEUTIC USES OF EPINUL PLURIPOTENT CELLS AND DIFFERENTIATED CELLS DERIVED THEREFROM
EP3601530A1 (en) * 2017-03-20 2020-02-05 IFOM Fondazione Istituto Firc di Oncologia Molecolare Method of generating 2 cell-like stem cells
AU2018281936A1 (en) * 2017-06-10 2020-01-30 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CN107729932B (zh) * 2017-10-10 2019-07-26 杭州智微信息科技有限公司 骨髓细胞标记方法和系统
KR102416171B1 (ko) 2018-10-02 2022-07-06 주식회사 스템온 세포의 리프로그래밍을 유도하는 리프로좀 및 그 제조 방법
JP7699552B2 (ja) 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
WO2021046186A1 (en) * 2019-09-04 2021-03-11 Vcell Therapeutics, Inc. Vaccine for treatment of cancer and method of making by stress reprogramming
EP4103694A4 (en) 2020-02-14 2024-03-20 Hackensack Meridian Health, Inc. TREATMENT MITOCHONDRIA FROM THROMBOCYTES AND METHOD FOR GENERATING MULTIPOTENT CELLS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097065A2 (en) * 2001-05-31 2002-12-05 Intercytex Limited Remodeling of somatic nuclei upon addition of pluripotent cell extracts
WO2007047766A2 (en) * 2005-10-14 2007-04-26 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
WO2008066630A2 (en) * 2006-10-27 2008-06-05 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods for reprogramming adult somatic cells and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963489A (en) 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
FR2687404B1 (fr) 1992-02-19 1994-05-20 Centre Nal Recherc Scientifique Peptides immunologiquement apparentes aux proteines d'un agent viral et leurs applications biologiques.
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US5672346A (en) 1992-07-27 1997-09-30 Indiana University Foundation Human stem cell compositions and methods
PT671923E (pt) 1992-10-09 2001-10-30 Advanced Tissue Sciences Inc Celulas de reserva do figado
US5753431A (en) * 1993-10-13 1998-05-19 Northeastern Ohio University Cholesterol 7 α-hydroxdylase gene regulatory elements and transcription factors
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9502022D0 (en) 1995-02-02 1995-03-22 Abuljadayel Ilham M S A method for preparing lymphohaematopoietic progenitor cells
WO2002057428A1 (en) 2000-10-30 2002-07-25 University Of Massachusetts Isolation of spore-like cells from tissues exposed to extreme conditions
US7575321B2 (en) 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
US7632681B2 (en) * 2003-12-02 2009-12-15 Celavie Biosciences, Llc Compositions and methods for propagation of neural progenitor cells
ES2364878T3 (es) * 2004-09-03 2011-09-15 Moraga Biotechnology Inc. Células madre de tipo blastómero totipotenciales no embrionarias y procedimientos de las mismas.
US20060084167A1 (en) 2004-10-16 2006-04-20 Cohenford Menashi A Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells
US20090298095A1 (en) * 2005-04-15 2009-12-03 The John Hopkins University Immortalization of cells including neuronal cells
FR2885368A1 (fr) * 2005-05-04 2006-11-10 Fred Zacouto Systemes et procedes de regeneration cellulaire et utilisations de telles cellules regenerees
CA2621161A1 (en) * 2005-09-08 2007-03-15 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Methods for promoting stem cell proliferation and survival
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
US20070190646A1 (en) * 2006-02-10 2007-08-16 The Trustees Of The University Of Pennsylvania Regulating stem cell differentiation by controlling matrix elasticity
WO2008038148A2 (en) * 2006-05-11 2008-04-03 Andrew Craig Boquest Stem cells and methods of making and using stem cells
EP2626416A3 (en) * 2007-04-07 2013-12-18 The Whitehead Institute for Biomedical Research Reprogramming of somatic cells
ES2409356T3 (es) * 2007-10-30 2013-06-26 Le Centre National De La Recherche Scientifique (Cnrs) Método de realización de un ensayo para neutralizar anticuerpos
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
US20090280518A1 (en) * 2008-05-12 2009-11-12 Massachusetts Institute Of Technology System for high throughput measurement of mechanical properties of cells
US9550975B2 (en) 2009-07-15 2017-01-24 Mari Dezawa SSEA-3 pluripotent stem cell isolated from body tissue
EP2312341B1 (en) * 2009-10-06 2019-05-29 Canon Kabushiki Kaisha Rear attachment lens and imaging optical system including the same
EP2554659A4 (en) 2010-04-02 2013-09-25 Riken PROCESS FOR PREPARING ES CELLS
KR20120002134A (ko) 2010-06-30 2012-01-05 서울대학교산학협력단 지방 기질 세포의 역분화를 유도하는 방법
EP2590695B1 (en) 2010-07-09 2024-11-20 GID BIO, Inc. Apparatus and methods relating to collecting and processing human biological material containing adipose

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002097065A2 (en) * 2001-05-31 2002-12-05 Intercytex Limited Remodeling of somatic nuclei upon addition of pluripotent cell extracts
WO2007047766A2 (en) * 2005-10-14 2007-04-26 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
WO2008066630A2 (en) * 2006-10-27 2008-06-05 Caritas St. Elizabeth Medical Center Of Boston, Inc. Methods for reprogramming adult somatic cells and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
D. Konno ET AL, "STAP cells are derived from ES cells", Nature, (2015-09-24), pages e4 - e5, URL: http://www.nature.com/nature/journal/v525/n7570/pdf/nature15366.pdf, (2015-11-09) *
DE LOS ANGELES, A. et al., "Failure to replicate the STAP cell phenomenon", Nature, 2015, Vol. 525, pages E6-E9 *
HARUKO OBOKATA ET AL, "Bidirectional developmental potential in reprogrammed cells with acquired pluripotency", NATURE, (2014-01-29), vol. 505, no. 7485, doi:10.1038/nature12969, ISSN 0028-0836, pages 676 - 680 *
HARUKO OBOKATA ET AL, "Retraction: Stimulus-triggered fate conversion of somatic cells into pluripotency", NATURE, United Kingdom, (2014-07-02), vol. 511, no. 7507, doi:10.1038/nature13598, ISSN 0028-0836, pages 112 - 112 *
HARUKO OBOKATA ET AL, "Stimulus-triggered fate conversion of somatic cells into pluripotency", NATURE, (2014-01-29), vol. 505, no. 7485, doi:10.1038/nature12968, ISSN 0028-0836, pages 641 - 647 *

Also Published As

Publication number Publication date
RU2014147093A (ru) 2016-06-10
AU2019203943B2 (en) 2021-10-07
US11963977B2 (en) 2024-04-23
RU2696071C2 (ru) 2019-07-30
AU2013251649A1 (en) 2014-11-06
SG10201809901SA (en) 2018-12-28
JP2025106394A (ja) 2025-07-15
KR20200084916A (ko) 2020-07-13
EP3483261A1 (en) 2019-05-15
JP2015516812A (ja) 2015-06-18
US20150110749A1 (en) 2015-04-23
JP2020182480A (ja) 2020-11-12
ES2972525T3 (es) 2024-06-13
EP2844738A4 (en) 2015-12-23
AU2019203943A1 (en) 2019-06-27
CN112048466A (zh) 2020-12-08
SG11201407768QA (en) 2015-01-29
CA2885576A1 (en) 2013-10-31
WO2013163296A1 (en) 2013-10-31
KR20150045935A (ko) 2015-04-29
JP2018183145A (ja) 2018-11-22
JP2023002805A (ja) 2023-01-10
EP2844738A1 (en) 2015-03-11
CN104718283A (zh) 2015-06-17
EP3483261B1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
AU2019203943B2 (en) Generating pluripotent cells de novo
AU2021286294B2 (en) Methods relating to pluripotent cells
HK40008457A (en) Generating pluripotent cells de novo
HK40041588A (en) Generating pluripotent cells de novo
HK40043770A (en) Methods relating to pluripotent cells

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

Free format text: FORMER APPLICANT(S): THE BRIGHAM AND WOMEN'S HOSPITAL, INC.; TOKOYO WOMEN'S MEDICAL UNIVERSITY; RIKEN

PC1 Assignment before grant (sect. 113)

Owner name: VCELL THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

FGA Letters patent sealed or granted (standard patent)